MK-4074 is primarily investigated for its potential therapeutic applications in metabolic disorders. It functions as a liver-targeted acetyl-CoA carboxylase (ACC) inhibitor, which plays a critical role in regulating fatty acid synthesis and oxidation. By inhibiting ACC, it helps reduce the production of fatty acids and enhances fatty acid oxidation, making it a promising candidate for treating conditions like non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Additionally, its liver-specific targeting minimizes systemic side effects, improving its safety profile. Research is ongoing to explore its efficacy in improving lipid metabolism and reducing liver fat accumulation in preclinical and clinical studies.